National Neisseria and Streptococcus Reference Center, Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark.
Vaccine. 2010 Mar 19;28(14):2642-7. doi: 10.1016/j.vaccine.2010.01.017. Epub 2010 Jan 20.
We evaluated the effectiveness of the heptavalent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) 1 year after PCV7's introduction in the childhood immunization programme through a nationwide cohort study based on laboratory surveillance data. There was a decline in the overall incidence of IPD from 19.4 to 17.1 cases per 100,000 population (incidence rate ratios (IRR) 0.87; 95% confidence interval (CI) [0.81-0.96]), and of meningitis from 1.56 to 1.16 (IRR 0.74; 95% CI [0.57-0.97]) comparing pre-PCV7 (years 2000-2007) and PCV7 (year 2008) periods. In children <2 years, the incidence decreased from 54 to 23 cases per 100,000 (IRR 0.43; 95% CI [0.29-0.62]) and for vaccine-serotypes from 36.7 to 7.7 (IRR 0.20; 95% CI [0.09-0.38]). The incidence of IPD declined approximately 10% (IRR 0.90; 95% CI [0.84-0.97]) in patients aged >or=2 years. The case fatality was 17% in both periods. The administration of PCV7 was followed by a marked decline in the incidence of IPD in both vaccinated and non-vaccinated individuals.
我们通过基于实验室监测数据的全国性队列研究,评估了七价肺炎球菌结合疫苗(PCV7)在儿童免疫计划中引入后 1 年对侵袭性肺炎球菌病(IPD)的有效性。总的 IPD 发病率从 19.4 例/10 万人下降到 17.1 例/10 万人(发病率比(IRR)0.87;95%置信区间(CI)[0.81-0.96]),脑膜炎从 1.56 例/10 万人下降到 1.16 例/10 万人(IRR 0.74;95%CI [0.57-0.97]),比较了 PCV7 前(2000-2007 年)和 PCV7 时期(2008 年)。在<2 岁的儿童中,发病率从 54 例/10 万人下降到 23 例/10 万人(IRR 0.43;95%CI [0.29-0.62]),疫苗血清型从 36.7 例/10 万人下降到 7.7 例/10 万人(IRR 0.20;95%CI [0.09-0.38])。≥2 岁患者的 IPD 发病率下降了约 10%(IRR 0.90;95%CI [0.84-0.97])。两个时期的病例病死率均为 17%。PCV7 接种后,无论是接种者还是未接种者,侵袭性肺炎球菌病的发病率都明显下降。